RUNX1 and acute myeloid leukemia: CRISPR/Cas9-mediated editing-out of RUNX1 enhancer (eR1) within its intragenic SE, or BRD4 depletion by shRNA, repressed RUNX1, inhibited cell growth and induced cell lethality in AML cells expressing mtRUNX1 [196].